12 Best Performing Biotech Stocks in 2023
Biotechnology is one of the hottest industries these days and one that has risen to prominence after the outbreak of the coronavirus pandemic.
Minerva Neurosciences Inc. (NERV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 4,322,747 | $23,991,246 | 2.19% | |
| 2. | Balyasny Asset Management Dmitry Balyasny | 4,257,000 | $23,626,350 | -1% | 0.03% |
| 3. | Logos Capital Arsani William | 3,288,777 | $18,252,712 | +3% | 0.79% |
| 4. | Farallon Capital Thomas Steyer | 2,365,000 | $13,125,750 | 0.06% | |
| 5. | Spruce Street Capital Alex Rosen And Simon Basseyn | 1,655,500 | $9,188,025 | 1.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.97 | 7,000 | $20,790.00 | 20,333 | 2020-09-10 | Filing | |
| $5.50 | 3,500 | $19,250.00 | 26,111 | 2019-06-27 | Filing | |
| $5.37 | 10,000 | $53,700.00 | 13,333 | 2019-06-26 | Filing | |
| $5.25 | 1,000 | $5,250.00 | 1,000 | 2019-06-26 | Filing | |
| $5.60 | 10,000 | $56,000.00 | 10,000 | 2019-06-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.76 | 3,641 | $13,690.16 | 68,994 | 2023-05-02 | Filing | |
| $3.85 | 23,753 | $91,449.05 | 72,635 | 2023-05-01 | Filing | |
| $3.85 | 22,082 | $85,015.70 | 51,324 | 2023-05-01 | Filing | |
| $4.48 | 3,580 | $16,038.40 | 17,518 | 2023-05-01 | Filing | |
| $0.88 | 55,635 | $48,958.80 | 163,553 | 2021-12-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,670,426 | $25,920,864 | 0.04% | |
| 2. | 4,386,027 | $24,320,520 | 0.01% | |
| 3. | 2,240,578 | $12,435,208 | 0% | |
| 4. | 2,175,802 | $12,075,701 | 10.68% | |
| 5. | 1,985,584 | $11,019,991 | 1.71% |
News See All
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Minerva Neurosciences First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Minerva Neurosciences Full Year 2022 Financial Results and Business Update Conference Call.
10 Best Biotech Stocks Under $10
In this article, we will look at the 10 best biotech stocks under $10.
Hedge Fund and Insider Trading News: Daniel Och, Steven Cohen, Warren Buffett, Nordic Cross Asset Management, Nikola Corp (NKLA), Nerdy, Inc. (NRDY), and More
The billionaire Daniel Och on Wednesday sued Sculptor Capital Management Inc, accusing the asset manager he helped found of letting its chief executive officer wield his power over its board to extract...
5 Best Biotech Penny Stocks To Buy Now
NuCana plc (NASDAQ:NCNA) is a British biotech firm which develops drug therapies to treat various forms of cancer.
5 Penny Stocks with Upcoming Growth Catalysts
Osceola Gold, Inc. (OTC:OSCI) is a precious metals mining company that is primarily focused on the exploration of gold. The company is based in Weirton, West Virginia.
Is NERV A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Hedge Fund Sentiment Is Stagnant On Minerva Neurosciences, Inc (NERV)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Buying Minerva Neurosciences, Inc (NERV)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
Hedge Fund Resource Center